- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02996097
Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
December 14, 2020 updated by: Johns Hopkins University
The purpose of this study is to compare the effects of fractional carbon dioxide (CO2) laser therapy immediately followed by intralesional steroid therapy against intralesional steroid therapy alone for the treatment of keloids.
Study Overview
Status
Completed
Conditions
Detailed Description
Intralesional corticosteroids remain the gold standard treatment for keloids.
However, more effective therapies are desperately desired.
Ablative fractional laser (AFL) treatment facilitates delivery of intralesional steroid more deeply and uniformly into the skin by creating vertical channels.
Recent studies have showed that fractional laser assisted steroid therapy can be effective in the treatment of keloids.
However the studies are lacking in comparing this treatment modality to the gold standard of intralesional steroids.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins School of Medicine, Department of Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female older than 17 at the screening visit;
- The subject is healthy, as determined by the investigator based on a medical evaluation including medical history;
- The subject has at least two keloids of comparative size and texture located on the same general anatomic location (trunk or back);
- The subject is willing and able to comply with the requirements of the protocol. In particular, subject must adhere to the visits schedule and concomitant therapy. The subject is willing to comply with the 4 week washout period;
- The subject has understood and signed an Informed Consent Form approved by the Institutional Review Board (IRB) prior to any investigational procedure
Exclusion Criteria:
Any subject who is meeting one or more of the following exclusion criteria at the screening visit and/or at the baseline visit will not be included in this study:
- The subject has an underlying known disease, a surgical or medical condition that in the opinion of the investigator might put the subject at risk
- The subject is pregnant or breastfeeding at the time of enrollment or is planning to become pregnant at any point during the study period
- The subject has a past history of coagulopathy
- The subject has an underlying dermatological disease that in the opinion of the investigator could interfere with the study evaluations
- The subject has used prohibited topical or systemic treatments without sufficient protocol-defined wash-out period prior to Baseline (checked at Screening and Baseline) or is unwilling to refrain from use during the study
- The subject is treated with anticoagulants or antiplatelet therapies
- The subject has a known allergy or sensitivity to any local anesthetic drug (e.g. EMLA or tetracaine 7%/lidocaine 23%) or a local antiseptic planned to be used for the laser.
- The subject is in an exclusion period from a previous study or is participating in another clinical trial
- The subject is an adult under guardianship or is hospitalized in a public or private institution, or is deprived of freedom
- The subject is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CO2 ablative laser plus intralesional triamcinolone acetonide
A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide.
One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
|
CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide.
One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
|
ACTIVE_COMPARATOR: Intralesional triamcinolone acetonide alone
A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide.
The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS)
Time Frame: Once every 4 weeks for 16 weeks
|
Data from POSAS Observer Scale will be collected and reported to assess vascularity, pigmentation, thickness, relief, pliability, and surface area of the keloids chosen for the research study.
Total score range: 6-60; Higher scores mean a worse outcome.
Mean composite score of the final visit was compared to the mean baseline score.
|
Once every 4 weeks for 16 weeks
|
Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS)
Time Frame: Once every 4 weeks for 16 weeks
|
Data from POSAS Observer Scale will be collected and reported to assess vascularity, pigmentation, thickness, relief, pliability, and surface area of the keloids chosen for the research study.
Total score range: 6-60; Higher scores mean a worse outcome.
Mean composite score of the final visit was compared to the mean baseline score.
|
Once every 4 weeks for 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ginette Okoye, MD, Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 1, 2016
Primary Completion (ACTUAL)
June 15, 2018
Study Completion (ACTUAL)
June 15, 2018
Study Registration Dates
First Submitted
December 14, 2016
First Submitted That Met QC Criteria
December 16, 2016
First Posted (ESTIMATE)
December 19, 2016
Study Record Updates
Last Update Posted (ACTUAL)
December 17, 2020
Last Update Submitted That Met QC Criteria
December 14, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Connective Tissue Diseases
- Fibrosis
- Cicatrix
- Collagen Diseases
- Keloid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- IRB00082453
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keloid
-
CHA UniversityCompletedHypertrophic or Keloid ScarsKorea, Republic of
-
Queen Mary University of LondonWithdrawn
-
SolitonEmergent Clinical Consulting, LLCCompleted
-
Sensus HealthcareUnknownKeloid ScarUnited States
-
Sensus HealthcareUnknown
-
University of UlmCompleted
-
NYU Langone HealthCompleted
-
Northwestern UniversityCompleted
-
Our Lady of the Lake HospitalLouisiana State University Health Sciences Center in New OrleansCompletedPost-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of KeloidsKeloid | Keloid Scar Following SurgeryUnited States
-
National Cheng-Kung University HospitalTainan Hospital, Ministry of Health and WelfareActive, not recruiting
Clinical Trials on The Lutronic electronic carbon dioxide (eCO2) Plus laser system
-
Sheba Medical CenterKaplan Medical Center; The Baruch Padeh Medical Center, PoriyaUnknownFemale Stress Urinary Incontinence
-
University of California, IrvineUniversity of Minnesota; Reliant Technologies, Inc. Mountain View, CACompleted
-
Massachusetts General HospitalTerminatedActinic Keratosis | Extensive Photodamage | History of Numerous Skin CancersUnited States
-
State University of New York at BuffaloCompletedExposure to Environmental Pollution | Adverse Effect of Unspecified General Anesthetic
-
Medstar Health Research InstituteCompletedVulvar Lichen SclerosusUnited States
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloEnrolling by invitationGenitourinary Symptoms | Postmenopausal Symptoms | Postmenopausal Atrophic VaginitisBrazil
-
Al-Azhar UniversityNot yet recruitingAtrophic Acne Scar
-
Ottawa Heart Institute Research CorporationTerminated
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloRecruitingBreast Cancer | Vaginal Atrophy | Vulva; AtrophyBrazil
-
University Hospital, GhentCompletedBowen's Disease | Superficial Basal Cell CarcinomaBelgium